EXTENDED PHENYTOIN SODIUM Drug Patent Profile
✉ Email this page to a colleague
When do Extended Phenytoin Sodium patents expire, and what generic alternatives are available?
Extended Phenytoin Sodium is a drug marketed by Amneal Pharms Ny, Ani Pharms, Lupin Ltd, Mylan, Sun Pharm Inds, Sun Pharm Inds (in), Taro, Unichem, Wockhardt, and Wockhardt Usa. and is included in eleven NDAs.
The generic ingredient in EXTENDED PHENYTOIN SODIUM is phenytoin sodium. There are twenty-one drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the phenytoin sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Extended Phenytoin Sodium
A generic version of EXTENDED PHENYTOIN SODIUM was approved as phenytoin sodium by WEST-WARD PHARMS INT on December 31st, 1969.
Summary for EXTENDED PHENYTOIN SODIUM
US Patents: | 0 |
Applicants: | 10 |
NDAs: | 11 |
Finished Product Suppliers / Packagers: | 17 |
Raw Ingredient (Bulk) Api Vendors: | 77 |
Clinical Trials: | 19 |
Patent Applications: | 1 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for EXTENDED PHENYTOIN SODIUM |
DailyMed Link: | EXTENDED PHENYTOIN SODIUM at DailyMed |
Recent Clinical Trials for EXTENDED PHENYTOIN SODIUM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Hospital Israelita Albert Einstein | Phase 4 |
Industria FarmacĂȘutica Health Meds | Phase 4 |
Cambridge University Hospitals NHS Foundation Trust | Phase 3 |